and you Good afternoon, thank Par. for joining Thanks, us.
committed is This finding for right been primary focus are of value-generating review strategic a now. for our This number our the one as the we the future. alternatives path Company quarter, our has to priority
We Partners assist to MTS have Health engaged in this process.
specific or partnering As potential otherwise providing could these and on further mergers and disclosure in-licensing, approved We unless announced a acquisitions. Directors these is not our asset determined has transaction July, on updates in include Board efforts, do plan transactions appropriate. that of
validate and studies path programs, including inhibitor SNS-XXX. value and in in PDK-X the and cancer, build inhibition mutated inhibitors KRAS investigating of reverse PDK-X vecabrutinib. lymphoma internal data study observed first-in-class in BCLX mouse development inhibitor studies and/or these October, of forward our to continuing presented In for in breast CDKX/X partnered first-in-class in a best SNS-XXX potential also we the of models cancers. on to vitro Combination and in role improve in are to We synergies We the support of our IND-enabling findings. needed preclinical resistance activity GXXC preclinical SNS-XXX, our are
in MEK-activated also mouse activity of anti-tumor xenograft SNS-XXX in further DLBCL characterization a model. CDKNXA-deleted demonstrating the in vivo, We graph shared
from meeting we Additional promising in next data emerge research a beginning investigator at is sponsored half medical first well, being to the year. as presented anticipate which of
PIXK continue optimization We profile work inhibitor the regimen to to expected through drug strategies. dose and address toxicities
may inhibitor we assessing the partnering BTK program. non-covalent include forward, our vecabrutinib, are which For best the path
the X advancing Phase in vecabrutinib ITK-driven an in decision as year, showed X/bX planned to this made we not inhibitor clinical trial X vecabrutinib investigation CLL. insufficient excellent relapsed/refractory BTK disease. well was although earlier reminder profile support in adults safety Vecabrutinib of to exhibited Further use and BTK to with resistant naïve other for or a BTK advance indications, combination Phase Phase therapies. the as include resistant could with As portion activity, in inhibitor into the the inhibitor
DAYXXX, inhibitor formerly by vosaroxin with Denovo One and We Day tact Biopharmaceuticals; partnered pan-RAF with two XXX, have Biopharma. our TAK also programs, partnered partnered
a we positive a to of this patients. meeting focused making pediatric clinical the are program Society objectives. In right-size approximately We XX% reduction of to will our lean a we the July, both in operating for announced efficiently to impact of workforce these Neuro-Oncology or this advancing these the in We achieve our and headcount forward company look remain Company. both to and XXX programs partners. capable presented at hands companies have month, be excited these of Emerging of from -- of data annual DAY
provide primarily $XX.X resulting offset cash from which million. items that, nine providing us million cash period debt. in as We the XX, in brings forward equity for and the over XXXX, net non-cash ended you operating XXXX, repaid outstanding quarter used was ended quarter, activities of adjustments look by loss as XXXX, XX, of for December capital September compared intended million, $XX.X million results. With third the most the in in to the sufficient million the to offering for These to our coming your call with $X.X questions. cash, let’s an proceeds me XXXX. $XX.X We updates months from $XX.X same equivalents of million to third the with financial as open and $XX Cash We to through of the also partially Operator? review months. restricted million $XX.X raised steps in of with compared to net are
